Venus Remedies Secures Indonesia Nod for Ceftazidime+Avibactam

Venus Remedies has secured marketing authorization from Indonesia’s drug regulator for ceftazidime+avibactam, marking a major step in its global growth plans. This also represents Venus’ first marketing authorisation in the anti-infective space within Indonesia.

This approval will enhance Venus’ coverage in Southeast Asia and gives momentum to Venus’ strategy for international expansion by allowing the company to sell its products in 10 ASEAN nations where they currently have approximately 370 approved injectable products. This demonstrates Venus’ increasing regulatory and commercial presence within Critical Care Therapeutics.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

“This approval reflects our continued focus on addressing antimicrobial resistance through clinically relevant therapies designed for hospital-based care,” said Saransh Chaudhary, president, global critical care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre. “It also reinforces our commitment to expanding access to life-saving anti-infective treatments in international markets.”

Ceftazidime + avibactam is combined into one product that treats serious multi-drug resistant infections like complicated urinary tract infections and complicated intra-abdominal infections by resistant Gram-negative bacteria. Avibactam acts by inhibiting beta-lactamase enzymes so as to restore the efficacy of ceftazidime.

Indonesia is one of the largest pharmaceutical markets in ASEAN and is also the most important market for antibiotics due to the number of individuals with infectious disease in the country. The total size of the ASEAN pharmaceutical market is expected to exceed USD 63.5 billion by 2029 providing excellent opportunities for Indian injectable manufacturers.

“With the approval of ceftazidime+avibactam, Venus Remedies enters the anti-infective segment in Indonesia, expanding beyond our existing presence in oncology,” said Aditi K Chaudhary, president, international business, Venus Remedies Limited. “This milestone reflects our long-term commitment to building a compliant and sustainable business in the region.”